Ishibashi M, Matsuda M, Osafune M, Nakano E, Fujioka H, Takaha M, Sonoda T, Kotake T, Watanabe S
Hinyokika Kiyo. 1983 Feb;29(2):121-9.
The circulating anti-RCC cytotoxic antibodies of eighteen RCC patients, preoperatively, and one inoperable case were studied by 51Cr release CDC and ADCC assays, using the cultured human RCC cell line, OUR-10. Circulating cytotoxic anti-RCC antibodies were detected in eight patients as CDC antibodies. The patients with a low pathological grade had a significantly higher percentage (P less than 0.05) of positive antibody responses.
使用培养的人肾癌细胞系OUR-10,通过51Cr释放补体依赖的细胞毒性(CDC)和抗体依赖的细胞介导的细胞毒性(ADCC)试验,对18例肾癌患者术前及1例无法手术的病例的循环抗肾癌细胞毒性抗体进行了研究。在8例患者中检测到循环细胞毒性抗肾癌细胞抗体,作为CDC抗体。病理分级低的患者抗体阳性反应百分比显著更高(P小于0.05)。